Veracyte VCYT Biopharmaceutical and other revenue — Accounts receivable

Similar metrics at other companies

LHBiopharma Laboratory Services — Accounts Receivable, before Allowance for Credit Loss

$808.4M+6.6%

HALOOther receivable — Accounts receivable, net and contract assets

$0—

ACIPharmacy — Receivables, net

$519.8M+12.0%

ARWRAccounts Receivable

$15.69M+563%

HALOOther product sales — Accounts receivable, net and contract assets

$54.39M-4.6%

CZROther — Accounts Receivable

$147M-8.1%

Questions, answered.

What is Veracyte's biopharmaceutical and other revenue — accounts receivable?

Veracyte (VCYT) reported biopharmaceutical and other revenue — accounts receivable of $1.1M in Q1 2026.

How has Veracyte's biopharmaceutical and other revenue — accounts receivable changed year-over-year?

Veracyte's biopharmaceutical and other revenue — accounts receivable decreased by 78.4% year-over-year, from $5.1M to $1.1M.

What is the long-term trend for Veracyte's biopharmaceutical and other revenue — accounts receivable?

Over 3 years (2022 to 2025), Veracyte's biopharmaceutical and other revenue — accounts receivable has grown at a -24.4% compound annual growth rate (CAGR), from $35.4M to $15.3M.

What does biopharmaceutical and other revenue — accounts receivable mean?

This metric represents the outstanding payments owed to the company by biopharmaceutical partners and research clients for services already rendered. It is a critical measure of the company's liquidity and the effectiveness of its credit and collection policies regarding its B2B service segment.